Press Releases

11.06.25

Press Release

Achieve Life Sciences Reports Third Quarter 2025 Financial Results; Provides Updates on Cytisinicline Program

One of Only Nine Therapies Chosen for the Inaugural FDA Commissioner’s National Priority Voucher for E-cigarette or Vaping Cessation Conference Call Scheduled for 8:30 AM EST Today, November 6, 2025 SEATTLE and VANCOUVER, British Columbia, November 6, 2025 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the…

/Read More

11.03.25

Press Release

Achieve Life Sciences Meets Key Milestones Advancing Cytisinicline NDA for Smoking Cessation

120-Day Safety Update Submitted to FDA ORCA-OL Long-Term Safety Trial Successfully Concluded DSMC Completes Final Review of Cytisinicline, Finds No Drug Safety Concerns SEATTLE and VANCOUVER, British Columbia, November 3, 2025 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as…

/Read More

10.29.25

Press Release

Achieve Life Sciences to Announce Third Quarter Financial Results and Host Conference Call and Webcast on November 6, 2025

SEATTLE and VANCOUVER, British Columbia, October 29, 2025 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessation, today announced it will report its third quarter 2025 financial results and provide a corporate…

/Read More

10.20.25

Press Release

Achieve Life Sciences Appoints Erik Atkisson as Chief Legal Officer

New life sciences executive brings more than 25 years of legal expertise spanning clinical and commercial stage biopharmaceutical companies SEATTLE and VANCOUVER, British Columbia, October 20, 2025 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline for treatment of nicotine dependence…

/Read More

10.17.25

Press Release

Achieve Life Sciences Receives FDA Commissioner’s National Priority Voucher for Cytisinicline for Treatment of Nicotine Dependence for E-cigarette or Vaping Cessation

Potential First-in-Class Treatment for Nicotine E-cigarette or Vaping Cessation Receives Unprecedented Expedited Review Pathway One of Only Nine Therapies Chosen for the FDA’s Inaugural National Priority Voucher Program SEATTLE and VANCOUVER, British Columbia, October 17, 2025 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development…

/Read More